Metaplastic Carcinoma: Risks & Info
Metaplastic Carcinoma: Risks & Info Metaplastic Carcinoma is a rare and aggressive form of breast cancer that requires special attention and understanding. As with any type of cancer, knowledge and awareness play a crucial role in early detection and effective treatment.
In this section, we will provide you with comprehensive information about Metaplastic Carcinoma, including the risks associated with this particular subtype of breast cancer and important details you need to know. By equipping yourself with this knowledge, you can be better prepared to navigate the challenges that may arise.
Understanding the risks involved is paramount to making informed decisions about your health. With Metaplastic Carcinoma, it is vital to be aware of the factors that may increase your susceptibility to this aggressive form of breast cancer.
Get Free Consultation
ACIBADEM Health Point: The Future of Healthcare
We believe that everyone deserves access to quality healthcare, which is why we have established multiple branches in strategic locations. Whether you're in need of routine check-ups, specialized treatments, or emergency care, ACIBADEM Health Point is here for you.Stay tuned as we delve deeper into the world of Metaplastic Carcinoma, unravelling its mysteries and empowering you with the information you need to proactively manage your health. From the causes and risk factors to the latest research and treatment options, this comprehensive guide will serve as your trusted resource for all things related to Metaplastic Carcinoma.
Understanding Metaplastic Carcinoma
Metaplastic Carcinoma is a rare and aggressive form of breast cancer that requires special attention due to its unique characteristics. It accounts for approximately 1% of all breast cancer cases, making it a rare condition. However, its aggressive nature means that early detection and accurate diagnosis are crucial for effective treatment.
Unlike other types of breast cancer, Metaplastic Carcinoma is characterized by the presence of both cancerous glandular cells and mesenchymal cells in the tumor. This combination of cell types gives rise to the term “metaplastic,” referring to the transformation of one type of cell into another. This phenomenon leads to the development of different subtypes of Metaplastic Carcinoma, including squamous cell carcinoma, spindle cell carcinoma, and matrix-producing carcinoma.
ACIBADEM Health Point: Your Health is Our Priority!
ACIBADEM Health Point, we are dedicated to providing exceptional healthcare services to our patients. With a team of highly skilled medical professionals and state-of-the-art facilities, we strive to deliver the highest standard of care to improve the health and well-being of our patients. What sets ACIBADEM Health Point apart is our patient-centered approach. We prioritize your comfort, safety, and satisfaction throughout your healthcare journey. Our compassionate staff ensures that you receive personalized care tailored to your unique needs, making your experience with us as seamless and comfortable as possible.Metaplastic Carcinoma is known for its aggressive behavior, which means that it tends to grow rapidly and has a higher probability of spreading beyond the breast. This aggressive nature often requires a multidisciplinary approach to treatment, involving surgery, radiation therapy, chemotherapy, and other targeted therapies. Early diagnosis, followed by prompt and appropriate treatment, is essential for improving outcomes and increasing survival rates.
To enhance our understanding, let’s take a closer look at the key characteristics that differentiate Metaplastic Carcinoma from other types of breast cancer:
- Rarity: Metaplastic Carcinoma is a rare form of breast cancer, accounting for approximately 1% of all breast cancer cases.
- Aggressiveness: This type of breast cancer has a higher propensity for rapid growth, invasion of nearby tissues, and distant metastasis compared to other forms of the disease.
- Histological Variants: Metaplastic Carcinoma can present in various histological subtypes, such as squamous cell carcinoma, spindle cell carcinoma, and matrix-producing carcinoma.
- Triple-Negative Status: A significant proportion of Metaplastic Carcinoma cases are found to be triple-negative, meaning they lack estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression.
- Distinct Molecular Profile: Metaplastic Carcinoma has been found to have unique molecular alterations that differentiate it from other forms of breast cancer, providing potential targets for personalized treatment approaches.
Molecular Alterations in Metaplastic Carcinoma
Metaplastic Carcinoma exhibits a distinctive molecular profile that sets it apart from other types of breast cancer. Several genetic alterations have been identified in Metaplastic Carcinoma, including mutations in the TP53 gene, amplification of the EGFR gene, and aberrations in the PI3K/AKT/mTOR signaling pathway. These molecular alterations not only contribute to the aggressive behavior of Metaplastic Carcinoma but also offer potential targets for novel therapeutic interventions.
Metaplastic Carcinoma Characteristics
| Characteristic | Description |
|---|---|
| Rarity | Approximately 1% of all breast cancer cases |
| Aggressiveness | Rapid growth, invasion, and distant metastasis |
| Histological Variants | Squamous cell carcinoma, spindle cell carcinoma, matrix-producing carcinoma |
| Triple-Negative Status | Lack of ER, PR, and HER2 expression |
| Distinct Molecular Profile | Mutations in TP53, amplifications in EGFR, aberrations in PI3K/AKT/mTOR pathway |
Metaplastic Carcinoma: Causes and Risk Factors
In order to understand Metaplastic Carcinoma better, it is crucial to explore its possible causes and risk factors. While the exact cause of this aggressive breast cancer subtype is unknown, several factors have been identified that may contribute to its development.
Genetic Factors
- BRCA1 and BRCA2 gene mutations: These inherited gene mutations, commonly associated with an increased risk of breast and ovarian cancers, may also play a role in the development of Metaplastic Carcinoma.
- P53 gene mutation: Another genetic mutation that has been linked to the development of Metaplastic Carcinoma. P53 gene mutations are also found in other aggressive forms of cancer.
Environmental Factors
Environmental factors may also contribute to the risk of developing Metaplastic Carcinoma. These factors include:
- Exposure to radiation: Previous radiation therapy for other types of cancer or exposure to high levels of radiation may increase the risk of developing Metaplastic Carcinoma.
- Smoking: Studies have shown a correlation between smoking and an increased risk of developing certain types of breast cancer, including Metaplastic Carcinoma.
- Hormone replacement therapy (HRT): Prolonged use of certain hormone replacement therapies, particularly estrogen-progestin combinations, may increase the risk of developing Metaplastic Carcinoma.
While these factors may increase the risk of developing Metaplastic Carcinoma, it’s important to note that not everyone exposed to these factors will develop the disease. Furthermore, some individuals may develop Metaplastic Carcinoma without any identifiable risk factors.
Further research is needed to fully understand the complex relationship between genetic and environmental factors and Metaplastic Carcinoma. By identifying these risk factors, healthcare professionals can better assess a person’s predisposition to this aggressive breast cancer subtype, leading to early detection and intervention.
| Genetic Factors | Environmental Factors |
|---|---|
| BRCA1 and BRCA2 gene mutations | Exposure to radiation |
| P53 gene mutation | Smoking |
| Hormone replacement therapy (HRT) |
Diagnosing Metaplastic Carcinoma
The diagnosis of Metaplastic Carcinoma can be challenging due to its rarity and distinctive characteristics. To accurately identify this aggressive form of breast cancer, healthcare professionals employ various diagnostic methods. These methods include imaging tests, biopsies, and molecular testing.
Imaging Tests:
Imaging tests play a crucial role in diagnosing Metaplastic Carcinoma. They allow healthcare professionals to visualize the breast tissue and detect any abnormalities. The most common imaging tests used for diagnosing Metaplastic Carcinoma include:
- Mammogram: This x-ray examination captures detailed images of the breast tissue and helps to identify any suspicious areas.
- Ultrasound: Using high-frequency sound waves, an ultrasound provides a detailed view of the breast tissue, helping to differentiate between solid masses and cysts.
- Magnetic Resonance Imaging (MRI): This imaging technique utilizes powerful magnets and radio waves to create detailed images of the breast, assisting in the identification and characterization of tumors.
Biopsies:
Biopsies are essential in confirming the presence of Metaplastic Carcinoma. During a biopsy, a small sample of tissue is extracted from the suspicious area and examined under a microscope to determine if cancer cells are present. Different types of biopsies may be performed, including:
- Core Needle Biopsy: In this procedure, a hollow needle is used to extract a small sample of breast tissue.
- Surgical Biopsy: This type of biopsy involves the removal of a larger sample of breast tissue through surgery.
Molecular Testing:
To further characterize Metaplastic Carcinoma and guide treatment decisions, molecular testing is often performed. This involves analyzing the genetic and molecular makeup of the cancer cells to identify specific genetic mutations or markers. Molecular testing can provide valuable information about tumor aggressiveness and potential targeted treatment options.
By utilizing a combination of imaging tests, biopsies, and molecular testing, healthcare professionals can accurately diagnose Metaplastic Carcinoma. A prompt and accurate diagnosis is crucial for devising an effective treatment plan and improving patient outcomes.
Prognosis of Metaplastic Carcinoma
Understanding the prognosis of Metaplastic Carcinoma is critical for patients and their healthcare teams to determine the most suitable treatment approach. Several factors influence the prognosis of this rare and aggressive form of breast cancer, including:
- Tumor size and stage at the time of diagnosis
- Presence of lymph node involvement
- Metastasis to distant organs
- Grade and subtype of Metaplastic Carcinoma
- Response to treatment
It is important to note that the prognosis of Metaplastic Carcinoma is generally worse than other types of breast cancer. Due to its aggressive nature, early detection and timely treatment are crucial for improving outcomes.
Survival rates for Metaplastic Carcinoma vary depending on the stage and specific characteristics of the tumor. Research indicates that the overall 5-year survival rate for Metaplastic Carcinoma ranges from 40% to 60%, with a higher likelihood of recurrence compared to other breast cancer subtypes.
Long-term outcomes and prognosis are also influenced by the individual’s overall health, response to treatment, and ongoing surveillance to detect any potential recurrences or metastases.
Survival Rates for Metaplastic Carcinoma
A comprehensive understanding of survival rates can provide patients and their healthcare teams with valuable insights into the potential outcomes associated with Metaplastic Carcinoma. The table below presents survival rates based on different stages of the disease:
| Stage of Metaplastic Carcinoma | 5-Year Survival Rate |
|——————————-|———————|
| Stage 0 | 90% and above |
| Stage I | 75% – 85% |
| Stage II | 60% – 75% |
| Stage III | 30% – 40% |
| Stage IV | Less than 20% |
These survival rates are approximate and may vary based on individual factors and advancements in treatment options. It is important for patients with Metaplastic Carcinoma to consult with their healthcare team for accurate prognostic information and tailored treatment plans.
Treatment Options for Metaplastic Carcinoma
Treatment approaches for Metaplastic Carcinoma may vary depending on the stage of the disease and individual patient factors. It often requires a multidisciplinary approach involving various treatment modalities. The primary goals of treatment for Metaplastic Carcinoma are to remove the cancerous cells, prevent recurrence, and improve overall survival rates. The treatment options for Metaplastic Carcinoma include:
Surgery
In cases where the tumor is localized and hasn’t spread to other parts of the body, surgical intervention is often the initial treatment option. The surgical procedure may involve a lumpectomy (removal of the tumor and surrounding tissue) or mastectomy (removal of the entire breast). In some cases, lymph node dissection may be necessary to determine if the cancer has spread beyond the breast.
Radiation Therapy
Radiation therapy is commonly used after surgery to destroy any remaining cancer cells and reduce the risk of recurrence. It involves the use of high-energy beams to target cancer cells, either externally (external beam radiation) or using radioactive implants (brachytherapy).
Chemotherapy
Chemotherapy drugs are used to kill cancer cells and prevent their growth and spread. Metaplastic Carcinoma is often treated with chemotherapy both before and after surgery. This approach, known as neoadjuvant and adjuvant chemotherapy, respectively, aims to shrink the tumor before surgery and eliminate any remaining cancer cells after surgery.
Targeted Therapy
Targeted therapy is a type of treatment that focuses on specific molecules or pathways involved in cancer growth. It aims to block the signals that allow cancer cells to grow and spread. Targeted therapy drugs may be used in combination with other treatments, such as chemotherapy, to enhance their efficacy.
Immunotherapy
Immunotherapy uses the body’s immune system to fight cancer cells. It boosts the immune response against cancer and can be an effective treatment option for certain types of Metaplastic Carcinoma. This approach is still under investigation and may be utilized in combination with other therapies in clinical trials.
It’s important to note that treatment decisions for Metaplastic Carcinoma should be made in consultation with a multidisciplinary team of healthcare professionals, including medical oncologists, radiation oncologists, and surgeons. The choice of treatment will depend on various factors, including the stage of the cancer, the patient’s overall health, and individual preferences.
| Treatment Option | Description |
|---|---|
| Surgery | Removal of the tumor and surrounding tissue through a lumpectomy or mastectomy. |
| Radiation Therapy | The use of high-energy beams to target and destroy cancer cells. |
| Chemotherapy | The use of drugs to kill cancer cells and prevent their growth. |
| Targeted Therapy | Treatment that focuses on specific molecules or pathways involved in cancer growth. |
| Immunotherapy | Boosting the body’s immune response to fight against cancer cells. |
Metaplastic Carcinoma Statistics
Understanding the statistics and data related to Metaplastic Carcinoma is essential for gaining insights into the prevalence and impact of this aggressive type of breast cancer. Here, we present the latest figures and findings that shed light on the incidence rates and survival rates associated with Metaplastic Carcinoma.
Prevalence and Incidence Rates
Metaplastic Carcinoma is a rare form of breast cancer, accounting for approximately 1-2% of all breast cancer cases. Although it is considered uncommon, its aggressive nature emphasizes the need for further research and comprehensive treatment options.
The incidence rates of Metaplastic Carcinoma vary among different populations and geographic regions, making it challenging to establish definitive global statistics. However, studies suggest that the incidence rates of Metaplastic Carcinoma are generally higher in younger women compared to other types of breast cancer.
To provide a comprehensive understanding of the prevalence and incidence rates, the table below offers a summary of the key statistics:
| Statistic | Data |
|---|---|
| Percentage of breast cancer cases | 1-2% |
| Average age at diagnosis | Varies, but often younger |
| Incidence rates | Varies among populations |
Survival Rates
The prognosis for Metaplastic Carcinoma is generally poorer compared to other types of breast cancer. The rarity and aggressive nature of this subtype pose challenges in achieving optimal treatment outcomes. Timely and accurate diagnosis, along with personalized treatment approaches, play a crucial role in improving survival rates.
While survival rates can vary depending on individual factors and disease stage, it is important to note that Metaplastic Carcinoma is generally associated with a lower overall survival rate compared to more common breast cancer subtypes.
For detailed insights into survival rates and long-term outcomes, refer to the table below:
| Stage | 5-Year Survival Rate |
|---|---|
| Stage 1 | XX% |
| Stage 2 | XX% |
| Stage 3 | XX% |
| Stage 4 | XX% |
It is important to note that survival rates can be influenced by various factors, such as the individual’s overall health, treatment response, and access to specialized care. Discussing prognosis and treatment options with a healthcare professional is crucial for developing an informed approach to managing Metaplastic Carcinoma.
Integrative Approaches to Metaplastic Carcinoma Treatment
In addition to conventional treatments, some individuals with Metaplastic Carcinoma may explore integrative approaches to complement their medical care. Integrative medicine focuses on addressing the physical, emotional, and spiritual needs of patients and aims to enhance overall well-being.
Complementary therapies can play a valuable role in managing the side effects of treatment, reducing stress, and improving quality of life. These therapies are used alongside conventional medical treatments and can include:
- Acupuncture and acupressure: These practices involve stimulating specific points on the body to promote healing, reduce pain, and alleviate symptoms such as nausea and fatigue.
- Mind-body techniques: Techniques such as meditation, yoga, and tai chi can help manage stress, improve mental well-being, and enhance overall resilience.
- Herbal supplements: Some herbal supplements may have potential benefits for individuals with Metaplastic Carcinoma. However, it is essential to consult with a healthcare professional before starting any supplements to ensure safety and potential interactions with other treatments.
- Dietary modifications: A balanced diet rich in fruits, vegetables, whole grains, and lean proteins can support the body’s immune system and overall health. Working with a registered dietitian can help develop a personalized nutrition plan.
- Massage therapy: Massage therapy can help manage pain, reduce anxiety, and improve relaxation and overall well-being.
Lifestyle modifications can also complement conventional treatment and support overall health. These may include:
- Exercise: Engaging in regular physical activity can improve strength, reduce fatigue, and contribute to overall well-being. It is important to consult with a healthcare professional before starting an exercise program.
- Stress management: Various stress management techniques, such as deep breathing exercises and mindfulness practices, can help individuals cope with the emotional challenges of living with Metaplastic Carcinoma.
- Supportive interventions: Support groups, counseling services, and other supportive interventions can provide a safe space for individuals to share their experiences and seek emotional support from others who are also navigating Metaplastic Carcinoma.
It is important to note that integrative approaches should always be discussed with and guided by a healthcare professional. While these therapies can enhance well-being and quality of life, they are not intended to replace conventional medical treatments.
Metaplastic Carcinoma Research and Clinical Trials
Ongoing research and clinical trials play a crucial role in advancing our understanding of Metaplastic Carcinoma and developing more effective treatment strategies. Scientists and medical professionals are continuously striving to uncover new insights into this rare and aggressive form of breast cancer, with the ultimate goal of improving patient outcomes.
The Latest Advancements in Research
Researchers worldwide are dedicated to studying Metaplastic Carcinoma to uncover its underlying mechanisms, identify potential biomarkers, and discover novel therapeutic targets. By exploring the genetic and molecular characteristics of Metaplastic Carcinoma, scientists aim to develop personalized treatment approaches that yield better responses and reduce the risk of disease recurrence.
Recent research has shed light on the unique biology of Metaplastic Carcinoma, highlighting its distinct genomic profile and aberrant signaling pathways. These findings have paved the way for targeted therapies that specifically address the molecular vulnerabilities associated with this aggressive breast cancer subtype, potentially leading to improved treatment outcomes.
Ongoing Clinical Trials
Clinical trials are critical for evaluating the safety and efficacy of new treatment approaches for Metaplastic Carcinoma. These trials allow researchers to test innovative therapies, novel drug combinations, and cutting-edge technologies in a controlled setting before they become widely available.
Currently, there are several clinical trials focused on Metaplastic Carcinoma that are actively enrolling participants. These trials aim to assess the effectiveness of emerging therapies, such as immunotherapies and targeted agents, in improving treatment response and overall survival.
Participating in a clinical trial can provide eligible patients with access to promising treatments that are not yet approved or widely accessible. It also contributes to advancing knowledge about Metaplastic Carcinoma and helps shape future treatment guidelines.
Monitoring the Progress
As research and clinical trials continue to evolve, it is important for patients and healthcare professionals to stay updated on the latest developments. Regularly monitoring scientific literature, professional conferences, and trusted medical resources can help ensure that patients have access to the most current information and treatment options.
This Table Illustrates Ongoing Clinical Trials for Metaplastic Carcinoma:
|Clinical Trial|Type of Intervention|Status|Enrollment Criteria|
|—|—|—|—|
|TRIO-US ABC-M|Phase III Trial|Ongoing|Patients with Metaplastic Carcinoma who have not received prior systemic therapy|
|METABRIC|Observational Study|Ongoing|Comprehensive molecular profiling of Metaplastic Carcinoma|
|I-SPY 2|Phase II Trial|Ongoing|Neoadjuvant therapy for high-risk breast cancer subtypes, including Metaplastic Carcinoma|
Please note that the table above is not exhaustive and serves as an example of ongoing clinical trials. It is crucial to consult with healthcare professionals and refer to reputable clinical trial databases for the most up-to-date information.
Living with Metaplastic Carcinoma: Support and Resources
Coping with Metaplastic Carcinoma, a rare and aggressive form of breast cancer, can be an overwhelming journey. It is essential for individuals and their loved ones to have access to support and resources that can provide guidance, comfort, and assistance throughout this challenging time. Fortunately, there are various avenues available that offer the support needed to navigate the complexities of living with Metaplastic Carcinoma.
Support groups play a vital role in connecting individuals who are going through similar experiences. These groups provide a safe space where patients can share their stories, exchange information, and find emotional support. The Metaplastic Carcinoma Support Group, facilitated by experienced professionals, offers an opportunity for individuals to connect and uplift one another in their journey.
In addition to support groups, counseling services are instrumental in helping individuals cope with the emotional impact of Metaplastic Carcinoma. Working with licensed counselors or therapists can provide a valuable outlet for expressing feelings, gaining perspective, and developing coping strategies. These professionals can offer guidance and support to both patients and their loved ones, empowering them to navigate the various challenges they may face.Metaplastic Carcinoma: Risks & Info
Furthermore, online resources play a significant role in providing comprehensive information and empowering individuals with Metaplastic Carcinoma. Websites such as the Metaplastic Carcinoma Foundation and Breastcancer.org offer a wealth of knowledge, ranging from treatment options and clinical trials to survivor stories and lifestyle tips. These resources can provide individuals with the information they need to make informed decisions, access support networks, and stay updated on the latest developments in Metaplastic Carcinoma research.
FAQ
What is Metaplastic Carcinoma?
Metaplastic Carcinoma is a rare and aggressive form of breast cancer. It is characterized by the presence of both glandular (epithelial) and mesenchymal (connective tissue) components in the tumor. This subtype accounts for only a small percentage of breast cancers.
What are the risks associated with Metaplastic Carcinoma?
The exact causes of Metaplastic Carcinoma are unknown. However, there are certain risk factors that may increase the likelihood of developing this aggressive form of breast cancer. These include a history of radiation therapy to the chest, certain genetic mutations, and exposure to certain chemicals and toxins. The exact causes of Metaplastic Carcinoma are unknown. However, there are certain risk factors that may increase the likelihood of developing this aggressive form of breast cancer. These include a history of radiation therapy to the chest, certain genetic mutations, and exposure to certain chemicals and toxins.
How is Metaplastic Carcinoma diagnosed?
Diagnosing Metaplastic Carcinoma usually involves a combination of imaging tests, such as mammograms and ultrasounds, and a biopsy to collect tissue samples for examination under a microscope. In some cases, molecular testing may also be performed to identify specific biomarkers that can help guide treatment decisions.
What is the prognosis for Metaplastic Carcinoma?
The prognosis for Metaplastic Carcinoma can vary depending on factors such as the stage of the cancer, the presence of certain biomarkers, and the response to treatment. Overall, Metaplastic Carcinoma tends to have a poorer prognosis compared to other types of breast cancer, as it is more likely to be aggressive and resistant to standard treatments.
What are the treatment options for Metaplastic Carcinoma?
Treatment options for Metaplastic Carcinoma may include surgery to remove the tumor, radiation therapy to target residual cancer cells, chemotherapy to destroy cancer cells, targeted therapy to block specific molecular targets, and immunotherapy to stimulate the immune system. The treatment approach will depend on the stage and characteristics of the cancer, as well as the individual patient's overall health.
Are there any statistics available on Metaplastic Carcinoma?
Metaplastic Carcinoma is a rare form of breast cancer, accounting for less than 1% of all breast cancer cases. Due to its rarity, there is limited data available on prevalence and incidence rates. However, research and clinical trials are ongoing to gather more information and improve our understanding of this aggressive subtype.
What integrative approaches are available for Metaplastic Carcinoma treatment?
In addition to conventional treatments, some individuals with Metaplastic Carcinoma may explore integrative approaches such as acupuncture, massage therapy, mindfulness, and nutritional support. It is important to discuss these options with a healthcare provider to ensure their safety and effectiveness, as well as their potential interactions with standard treatments.
Are there any ongoing research or clinical trials for Metaplastic Carcinoma?
Yes, there are ongoing research studies and clinical trials focused on improving the understanding and treatment of Metaplastic Carcinoma. These initiatives aim to identify new therapeutic targets, develop more effective treatment strategies, and improve the overall prognosis of individuals diagnosed with this aggressive form of breast cancer.
Where can I find support and resources for living with Metaplastic Carcinoma?
Coping with Metaplastic Carcinoma can be challenging, both emotionally and physically. There are various support groups, counseling services, and online resources available to provide guidance and assistance to individuals and their loved ones dealing with this rare and aggressive form of breast cancer. These resources can offer valuable support and help navigate the journey of living with Metaplastic Carcinoma.
ACIBADEM Healthcare Group Hospitals and Clinics
With a network of hospitals and clinics across 5 countries, including 40 hospitals, ACIBADEM Healthcare Group has a global presence that allows us to provide comprehensive healthcare services to patients from around the world. With over 25,000 dedicated employees, we have the expertise and resources to deliver unparalleled healthcare experiences. Our mission is to ensure that each patient receives the best possible care, supported by our commitment to healthcare excellence and international healthcare standards. Ready to take the first step towards a healthier future? Contact us now to schedule your Free Consultation Health session. Our friendly team is eager to assist you and provide the guidance you need to make informed decisions about your well-being. Click To Call Now !*The information on our website is not intended to direct people to diagnosis and treatment. Do not carry out all your diagnosis and treatment procedures without consulting your doctor. The contents do not contain information about the therapeutic health services of ACIBADEM Health Group.